Richard M. Stone
Dana-Farber Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Richard M. Stone as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 03:55 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT00651261 · Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaAlliance for Clinical Trials in Oncology · completed · Leukemia · study chair
- Ph2NCT00136461 · A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)Dana-Farber Cancer Institute · completed · Acute Myelogenous Leukemia, Myelodysplastic Syndrome · principal investigator
- Ph2NCT00136448 · High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for Patients With Acute Myelogenous Leukemia (AML)Dana-Farber Cancer Institute · completed · Acute Myelogenous Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 03:55 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 11 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- SPORE in LeukemiaP50CA298970 · NCI · DANA-FARBER CANCER INST · fiscal years 2026 · $2,433,959 awarded in 2026Same name and institution; not confirmed by an ID
- Clinical Research SupportP01CA066996 · NCI · DANA-FARBER CANCER INST · fiscal years 2008 to 2024 · $304,767 awarded in 2024Same name and institution; not confirmed by an ID
- SPORE in Myeloid MalignanciesP50CA206963 · NCI · DANA-FARBER CANCER INST · fiscal years 2017 to 2021 · $2,138,999 awarded in 2021Same name and institution; not confirmed by an ID
- PROTEIN KINASE C BASED ANTILEUKEMIC THERAPYR29CA068252 · NCI · DANA-FARBER CANCER INST · fiscal years 1995 to 1999 · $125,406 awarded in 1999Same name and institution; not confirmed by an ID
- DIFFERENTIATION SIGNAL TRANSDUCTION IN MYELOID LEUKEMIAK08CA001352 · NCI · DANA-FARBER CANCER INST · fiscal years 1990 to 1994 · $85,775 awarded in 1994Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 03:55 UTC. The ranking covers the 200 most relevant of 109 PubMed records, and a shared surname and initials can bring in a namesake. All 109 on PubMed
- 2,731 citationsRCR 52.7
- 1,934 citationsRCR 65.6
- Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.J Clin Oncol · 20021,498 citationsRCR 25.6
- 1,317 citationsRCR 25.5
- 1,254 citationsRCR 40.6
- 1,249 citationsRCR 38.4
- 1,005 citationsRCR 29.4
- 913 citationsRCR 16.4
- 817 citationsRCR 30.9
- Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.N Engl J Med · 2018789 citationsRCR 27.0